Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety Study of S-567123 in Healthy Adults and Elderly
jRCT2031250614Phase 1Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of S-567123 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Safety and tolerability. Started Jan 2026; status: active, not recruiting.
02
Drugs
S-567123
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031250614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250614.